Summary
Abbott Laboratories reported solid financial results for the third quarter and the first nine months of 2002. Net sales increased by 3.8% for the quarter and 8.5% for the nine-month period compared to the prior year, driven by growth in Pharmaceutical and International segments. Net earnings also showed significant improvement, with diluted earnings per share rising to $0.46 for the quarter from $0.40 in the prior year. The company's balance sheet remains strong, with increased working capital and robust operating cash flows. However, investors should note the ongoing legal proceedings, including an industry-wide investigation into the enteral nutritional business and issues related to the FDA consent decree for diagnostics manufacturing, which could materially impact future results.
Key Highlights
- 1Net sales for the third quarter of 2002 increased by 3.8% to $4.34 billion compared to the same period in 2001.
- 2For the first nine months of 2002, net sales grew by 8.5% to $12.85 billion, largely driven by the acquisition of BASF's pharmaceutical business and strong international performance.
- 3Diluted earnings per share for the third quarter of 2002 were $0.46, an increase from $0.40 in the prior year's quarter.
- 4Net earnings for the nine months ended September 30, 2002, significantly increased to $2.17 billion from $0.94 billion in the prior year.
- 5Abbott maintained a strong cash flow from operating activities, generating $3.0 billion for the first nine months of 2002.
- 6The company is facing ongoing legal proceedings, including an industry-wide investigation into its enteral nutritional business, which could have a material adverse effect on cash flows and operations.
- 7A one-time pre-tax charge of $129 million was recorded in the second quarter of 2002 related to the U.S. FDA consent decree for diagnostics manufacturing, with ongoing EPS expected to be negatively impacted.